Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In James Hardie (JHX) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in James Hardie and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally ...

Core Viewpoint - BellRing Brands Inc. is under investigation for potential violations of federal securities laws and unlawful business practices, following a significant drop in stock price after revealing slowed sales growth expectations [1][2]. Group 1: Company Performance - During the second quarter earnings call on May 6, 2025, BellRing Brands disclosed that certain customers are optimizing their inventories, leading to a forecasted sales growth slowdown to "low-single-digits" for the third quarter [2]. - Following this announcement, BellRing Brands' stock price fell by nearly 19% [2]. Group 2: Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against BellRing Brands on behalf of its stockholders, focusing on possible violations of federal securities laws [1]. - The law firm is reaching out to long-term stockholders who may have suffered losses and is encouraging them to participate in the investigation [3].

Core Viewpoint - The Schall Law Firm is investigating Capricor Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information regarding its Biologics License Application for deramiocel, a treatment for Duchenne muscular dystrophy cardiomyopathy [1][2]. Group 1 - The investigation is centered on whether Capricor issued false or misleading statements or failed to disclose important information to investors [2]. - On May 5, 2025, Capricor announced that the FDA confirmed its intent to hold an advisory committee meeting regarding the Company's BLA for deramiocel [2].